Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Cream in Genital Vitiligo
NCT05750823Phase 2Completed
- Sponsor
- Incyte
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib cream in Vitiligo, sponsored by Incyte. Primary endpoint: Percentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of '4 - A Lot Less Noticeable' or '5 - No Longer Noticeable' at 48 weeks. Started Apr 2023; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT05750823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750823.